Back to results
US 2026/0028644 A1Published application
Pseudovirus based neutralization assay for evaluating vaccine immunogenicity
AssigneeNovavax, Inc.
InventorsZhaohui CAI, Raj KALKERI
Life of this patent
Estimating the term…
Abstract
Provided herein are pseudoviruses expressing a SARS-CoV-2 S glycoprotein. Also provided herein are assays that employ the pseudoviruses to evaluate the immunogenicity of a biological sample against a SARS-CoV-2 virus or variant thereof. Also provided herein are methods of evaluating the immunogenicity of a COVID-19 vaccine using the assays.
Claims23
1-36. (canceled)
A pseudovirus encoding:
- (i) a SARS-CoV-2 Spike (S) glycoprotein;
- (ii) one or more of Rev, Tat, Gag, and Pol proteins;
- and
- (iii) a reporter protein.
1 more element
Dependencies are inferred from the claim text.